Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

@article{Wu2011ImpactOL,
  title={Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.},
  author={Yulin Wu and Mayur M. Amonkar and Beth H Sherrill and Joyce O'Shaughnessy and Carla Ellis and Jos{\'e} Baselga and Kimberly L. Blackwell and Harold J. Burstein},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2011},
  volume={22 12},
  pages={2582-90}
}
BACKGROUND Progression-free survival (PFS) was significantly longer for the lapatinib plus trastuzumab (L+T) arm than for L alone in a phase III, randomized, open-label study of women with human epidermal growth factor receptor 2 positive metastatic breast cancer who had documented progression on at least one T-containing regimen in the metastatic setting. This analysis focused on impact of treatments on health-related quality of life (HRQOL). METHODS HRQOL was assessed using the Functional… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

A confidence interval for the median survival

R Brookmeyer, J. Crowley
Biometrics • 1982
View 5 Excerpts
Highly Influenced

Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy

KL Blackwell, HJ Burstein, GW. Sledge
Cancer Res • 2009
View 9 Excerpts
Highly Influenced

Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer

B Sherrill, A Di Leo, MM Amonkar
Curr Med Res Opin • 2010

Evolving novel anti-HER2 strategies.

The Lancet. Oncology • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…